Neuroprotective effects of andrographolide in a rat model of permanent cerebral ischaemia

BACKGROUND AND PURPOSE Andrographolide is a diterpenoid lactone isolated from a traditional medicinal herb, Andrographis paniculata. It possesses potent anti‐inflammatory activity. The present study examined potential therapeutic effects of andrographolide on cerebral ischaemia using a rat model with permanent middle cerebral artery occlusion (pMCAO).

[1]  Julie S. Jurenka,et al.  Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. , 2007, Alternative medicine review : a journal of clinical therapeutic.

[2]  W. Wong,et al.  A Novel Antiinflammatory Role for Andrographolide in Asthma via Inhibition of the Nuclear Factor-kb Pathway , 2022 .

[3]  N. Mackman,et al.  NF-κB Transcription Factor p50 Critically Regulates Tissue Factor in Deep Vein Thrombosis* , 2009, Journal of Biological Chemistry.

[4]  C. Coutelle,et al.  In utero gene therapy: The case for , 1999, Nature Medicine.

[5]  P. Wood,et al.  Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. , 1995, Neurological research.

[6]  Qing Wang,et al.  The inflammatory response in stroke , 2007, Journal of Neuroimmunology.

[7]  B. Fang,et al.  Activity of andrographolide and its derivatives against influenza virus in vivo and in vitro. , 2009, Biological & pharmaceutical bulletin.

[8]  Ning Zhang,et al.  Edaravone Reduces Early Accumulation of Oxidative Products and Sequential Inflammatory Responses After Transient Focal Ischemia in Mice Brain , 2005, Stroke.

[9]  D. Stephenson,et al.  Global ischemia activates nuclear factor-kappa B in forebrain neurons of rats. , 1997, Stroke.

[10]  E. Warburton,et al.  Inflammation and ischaemic stroke , 2007, Current opinion in neurology.

[11]  V. Feigin,et al.  Stroke epidemiology in the developing world , 2005, The Lancet.

[12]  D. Graham,et al.  Focal Cerebral Ischaemia in the Rat: 1. Description of Technique and Early Neuropathological Consequences following Middle Cerebral Artery Occlusion , 1981, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  Y. Samson,et al.  [Inflammation and ischaemic stroke: current status and future perspectives]. , 2005, Revue neurologique.

[14]  H. Canatan,et al.  In vitro and in vivo anti-inflammatory effects of andrographolide. , 2009, International immunopharmacology.

[15]  C. Aromdee,et al.  Analgesic, antipyretic, anti-inflammatory and toxic effects of andrographolide derivatives in experimental animals , 2009, Archives of pharmacal research.

[16]  L. Pitts,et al.  Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. , 1986, Stroke.

[17]  M. Moskowitz,et al.  Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.

[18]  Jiankuan Li,et al.  Six new andrographolide metabolites in rats. , 2003, Chemical & pharmaceutical bulletin.

[19]  A. Martin-Villalba,et al.  NF-kappaB is activated and promotes cell death in focal cerebral ischemia. , 1999, Nature medicine.

[20]  J. Larrick,et al.  Hypoglycemic and beta cell protective effects of andrographolide analogue for diabetes treatment , 2009, Journal of Translational Medicine.

[21]  J. Garcìa,et al.  Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. , 1995, The American journal of pathology.

[22]  Li-Kwan Chang,et al.  Inhibition of the epstein-barr virus lytic cycle by andrographolide. , 2008, Biological & pharmaceutical bulletin.

[23]  P. Chan,et al.  A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Padh,et al.  Andrographolide: A New Plant-Derived Antineoplastic Entity on Horizon , 2011, Evidence-based complementary and alternative medicine : eCAM.

[25]  J. Geng,et al.  Andrographolide inhibits NF-kappaBeta activation and attenuates neointimal hyperplasia in arterial restenosis. , 2007, Cell research.

[26]  Y. Samson,et al.  Inflammation et accident ischmique crbral aigu. Donnes actuelles et perspectives , 2005 .

[27]  Á. Chamorro,et al.  The harms and benefits of inflammatory and immune responses in vascular disease. , 2006, Stroke.

[28]  S. Malawista,et al.  Analysis of the PKC-γ-Related Immunocrossreactive Region of a Novel Leukocyte Protein γ-rp , 1999, Inflammation.

[29]  Michael Schroeter,et al.  Inflammation and glial responses in ischemic brain lesions , 1998, Progress in Neurobiology.

[30]  M. Ross,et al.  Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia , 1999, Acta Neuropathologica.

[31]  Zheng-Tao Wang,et al.  Andrographolide inhibits the production of TNF-alpha and interleukin-12 in lipopolysaccharide-stimulated macrophages: role of mitogen-activated protein kinases. , 2006, Biological & pharmaceutical bulletin.

[32]  W. Lü.  Prospect for study on treatment of AIDS with traditional Chinese medicine. , 1995, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[33]  M. Ross,et al.  Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Larrick,et al.  Synthesis and evaluation of antibacterial activities of andrographolide analogues. , 2009, European journal of medicinal chemistry.

[35]  J. Geng,et al.  Andrographolide Attenuates Inflammation by Inhibition of NF-κB Activation through Covalent Modification of Reduced Cysteine 62 of p501 , 2004, The Journal of Immunology.

[36]  J. Hancke,et al.  Andrographolide inhibits IFN-γ and IL-2 cytokine production and protects against cell apoptosis , 2005 .

[37]  Bin Liu,et al.  Andrographolide Reduces Inflammation-Mediated Dopaminergic Neurodegeneration in Mesencephalic Neuron-Glia Cultures by Inhibiting Microglial Activation , 2004, Journal of Pharmacology and Experimental Therapeutics.

[38]  F. Barone,et al.  Ischemic stroke intervention requires mixed cellular protection of the penumbra. , 2009, Current opinion in investigational drugs.

[39]  R. M. Adibhatla,et al.  Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. , 2008, CNS & neurological disorders drug targets.

[40]  P. Lapchak.  Development of thrombolytic therapy for stroke: a perspective , 2002, Expert opinion on investigational drugs.

[41]  Y. Itoyama,et al.  Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. , 1995, Stroke.

[42]  I. Zhari,et al.  Absorption of andrographolides from Andrographis paniculata and its effect on CCl(4)-induced oxidative stress in rats. , 2009, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[43]  D. Schneider,et al.  Reduced infarct volume and differential effects on glial cell activation after hyperbaric oxygen treatment in rat permanent focal cerebral ischaemia , 2005, The European journal of neuroscience.

[44]  F. Barone,et al.  Inflammatory Mediators and Stroke: New Opportunities for Novel Therapeutics , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  S. L. Mehta,et al.  Molecular targets in cerebral ischemia for developing novel therapeutics , 2007, Brain Research Reviews.

[46]  Alan D. Lopez,et al.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study , 1997, The Lancet.

[47]  Jill Hendren,et al.  Normobaric Hyperoxia Reduces the Neurovascular Complications Associated With Delayed Tissue Plasminogen Activator Treatment in a Rat Model of Focal Cerebral Ischemia , 2009, Stroke.

[48]  J. Hancke,et al.  Immunopharmacology and In fl ammation Andrographolide reduces IL-2 production in T-cells by interfering with NFAT and MAPK activation , 2009 .

[49]  J. Satayavivad,et al.  Inhibitory effect of Andrographis paniculata extract and its active diterpenoids on platelet aggregation. , 2006, European journal of pharmacology.

[50]  D. Stephenson,et al.  Global Ischemia Activates Nuclear Factor-κB in Forebrain Neurons of Rats , 1997 .

[51]  M. Chopp,et al.  Atorvastatin Extends the Therapeutic Window for tPA to 6 h after the Onset of Embolic Stroke in Rats , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[52]  Azhar A. Rahman,et al.  Antinociceptive and Antiedematogenic Activities of Andrographolide Isolated From Andrographis paniculata in Animal Models , 2010, Biological research for nursing.

[53]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[54]  S. -. Wu,et al.  Antioxidant, antioedema and analgesic activities of Andrographis paniculata extracts and their active constituent andrographolide , 2009, Phytotherapy research : PTR.

[55]  J. Hancke,et al.  Andrographolide inhibits IFN-gamma and IL-2 cytokine production and protects against cell apoptosis. , 2005, Planta medica.

[56]  R. Willette,et al.  Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. , 1997, Stroke.

[57]  K. Decker.  [Tumor necrosis factor alpha]. , 1992, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis.

[58]  J. Geng,et al.  Andrographolide inhibits NF-κB activation and attenuates neointimal hyperplasia in arterial restenosis , 2007, Cell Research.

[59]  A. Kalergis,et al.  Inhibition of Nuclear Factor-κB Enhances the Capacity of Immature Dendritic Cells to Induce Antigen-Specific Tolerance in Experimental Autoimmune Encephalomyelitis , 2006, Journal of Pharmacology and Experimental Therapeutics.

[60]  A. Kalergis,et al.  Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. , 2006, The Journal of pharmacology and experimental therapeutics.

[61]  S. Tsui,et al.  Andrographolide Up-Regulates Cellular-Reduced Glutathione Level and Protects Cardiomyocytes against Hypoxia/Reoxygenation Injury , 2008, Journal of Pharmacology and Experimental Therapeutics.

[62]  B. Halliwell,et al.  Hydrogen Sulfide Is a Mediator of Cerebral Ischemic Damage , 2006, Stroke.

[63]  O W Witte,et al.  Phagocytic response in photochemically induced infarction of rat cerebral cortex. The role of resident microglia. , 1997, Stroke.

[64]  Guo-Yuan Yang,et al.  Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. , 1998, Neuroreport.

[65]  Kyung-Su Park,et al.  NF-kappaB inhibition leads to increased synthesis and secretion of MIF in human CD4+ T cells. , 2009, Immunology letters.

[66]  T. Back.  Pathophysiology of the Ischemic Penumbra—Revision of a Concept , 1998, Cellular and Molecular Neurobiology.

[67]  M. Karjalainen‐Lindsberg,et al.  Nuclear Factor- (cid:1) B Contributes to Infarction After Permanent Focal Ischemia , 2004 .